Form 8-K - Current report
SEC Accession No. 0001213900-26-106651
Filing Date
2026-10-05
Accepted
2026-10-05 08:00:38
Documents
11
Period of Report
2026-09-30
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0307484-8k_jasper.htm   iXBRL 8-K 38061
  Complete submission text file 0001213900-26-106651.txt   201643

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE jspr-20260930.xsd EX-101.SCH 3014
3 XBRL LABEL FILE jspr-20260930_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE jspr-20260930_pre.xml EX-101.PRE 22358
14 EXTRACTED XBRL INSTANCE DOCUMENT ea0307484-8k_jasper_htm.xml XML 3117
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

EIN.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 261438812
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)